Literature DB >> 18972188

Efficacy of mouth rinse in preventing oral mucositis in patients receiving high-dose cytarabine for allogeneic hematopoietic stem cell transplantation.

Takehiko Mori1,2, Kaori Hasegawa3, Ai Okabe3, Natsuki Tsujimura3, Yusuke Kawata3, Tomoko Yashima3, Naoko Kobayashi3, Sakiko Kondo3, Yoshinobu Aisa4, Jun Kato4,5, Kazuyuki Tsunoda6, Tetsuo Nagai6, Taneaki Nakagawa6, Naoyuki Shigematsu7, Atsushi Kubo7, Yasuo Ikeda4, Shinichiro Okamoto4.   

Abstract

High-dose cytarabine is one of the major components of the conditioning regimen for hematopoietic stem cell transplantation (HSCT), and frequently causes severe oral mucositis. We have recently demonstrated that cytarabine is excreted into the saliva in patients receiving high-dose cytarabine, and proposed that it might locally and directly contribute to the development of oral mucositis. Therefore, this study was performed to assess whether removing the excreted cytarabine in the saliva by intensive mouth rinse during high-dose cytarabine infusion could reduce the incidence of oral mucositis. Fifteen patients with hematologic malignancies undergoing allogeneic HSCT who received total body irradiation (12 Gy) and high-dose cytarabine at a dose of 3 g/m(2) every 12 h for 4 days as a conditioning were evaluated. Patients were instructed to rinse their mouths using ice-cold water every 10 min, starting simultaneously with the 2-h cytarabine infusion and continuing up to 1 h after completion of each infusion. Oral mucositis was graded on a daily basis according to the National Cancer Institute, Common Toxicity Criteria. Thirty-five patients who previously underwent the same conditioning without mouth rinse served as controls. The incidence of Grades 2-3 and Grade 3 oral mucositis was significantly reduced in patients who performed mouth rinse as compared with the controls (40 vs. 80%, P = 0.009; 0 vs. 25. 7%, P = 0.02). In conclusion, mouth rinse during and shortly after high-dose cytarabine infusion could be an effective and inexpensive measure in reducing the incidence of moderate to severe oral mucositis caused by high-dose cytarabine. This finding strongly suggests the role of cytarabine excretion in the saliva in the development of cytarabine-associated oral mucositis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18972188     DOI: 10.1007/s12185-008-0181-5

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  23 in total

1.  Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients.

Authors:  Takehiko Mori; Rie Yamazaki; Yoshinobu Aisa; Tomonori Nakazato; Masumi Kudo; Tomoko Yashima; Sakiko Kondo; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Support Care Cancer       Date:  2006-01-28       Impact factor: 3.603

2.  Total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine as a conditioning regimen in allogeneic hematopoietic stem cell transplantation for advanced myelodysplastic syndrome: a single-institute experience.

Authors:  T Mori; Y Aisa; A Yokoyama; T Nakazato; R Yamazaki; T Shimizu; A Mihara; J Kato; R Watanabe; N Takayama; Y Ikeda; S Okamoto
Journal:  Bone Marrow Transplant       Date:  2007-01-15       Impact factor: 5.483

Review 3.  Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment.

Authors:  J Filicko; H M Lazarus; N Flomenberg
Journal:  Bone Marrow Transplant       Date:  2003-01       Impact factor: 5.483

4.  Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII.

Authors:  D Crivellari; M Bonetti; M Castiglione-Gertsch; R D Gelber; C M Rudenstam; B Thürlimann; K N Price; A S Coates; C Hürny; J Bernhard; J Lindtner; J Collins; H J Senn; F Cavalli; J Forbes; A Gudgeon; E Simoncini; H Cortes-Funes; A Veronesi; M Fey; A Goldhirsch
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

5.  Toxicity of high dose Ara-C in children and adolescents.

Authors:  N J Barrios; C K Tebbi; A I Freeman; M L Brecher
Journal:  Cancer       Date:  1987-07-15       Impact factor: 6.860

Review 6.  Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis - are there new strategies?

Authors:  M Karthaus; C Rosenthal; A Ganser
Journal:  Bone Marrow Transplant       Date:  1999-11       Impact factor: 5.483

7.  Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.

Authors:  R A Popescu; A Norman; P J Ross; B Parikh; D Cunningham
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

8.  Excretion of cytosine arabinoside in saliva after its administration at high doses.

Authors:  Takehiko Mori; Rie Yamazaki; Tomonori Nakazato; Yoshinobu Aisa; Sawako Enoki; Masaaki Arai; Yasuo Ikeda; Shinichiro Okamoto
Journal:  Anticancer Drugs       Date:  2006-06       Impact factor: 2.248

9.  Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial.

Authors:  B N Stein; N J Petrelli; H O Douglass; D L Driscoll; G Arcangeli; N J Meropol
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

10.  Inhibition of fluorouracil-induced stomatitis by oral cryotherapy.

Authors:  D J Mahood; A M Dose; C L Loprinzi; M H Veeder; L M Athmann; T M Therneau; J M Sorensen; D K Gainey; J A Mailliard; N L Gusa
Journal:  J Clin Oncol       Date:  1991-03       Impact factor: 44.544

View more
  2 in total

Review 1.  Systematic review of basic oral care for the management of oral mucositis in cancer patients.

Authors:  Deborah B McGuire; Janet S Fulton; Jumin Park; Carlton G Brown; M Elvira P Correa; June Eilers; Sharon Elad; Faith Gibson; Loree K Oberle-Edwards; Joanne Bowen; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2013-09-10       Impact factor: 3.603

2.  Prevention of cytarabine-induced kerato-conjunctivitis by eye rinse in patients receiving high-dose cytarabine and total body irradiation as a conditioning for hematopoietic stem cell transplantation.

Authors:  Takehiko Mori; Jun Kato; Akiko Yamane; Yoshinobu Aisa; Yusuke Kawata; Mayu Ichimura; Chiaki Tsuneyama; Tomoko Yashima; Yoko Ogawa; Kazuo Tsubota; Naoyuki Shigematsu; Takayuki Shimizu; Shinichiro Okamoto
Journal:  Int J Hematol       Date:  2011-08-19       Impact factor: 2.490

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.